Autolus Therapeutics plc American Depositary Share (AUTL) Stock Price

AUTLStock

$1.60−4.76%52W

Market Cap$425.86M

P/E—

PEG Ratio—

Div yield—

Beta2.37

AUTL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.80%

Price vs S&P 500 (4W)-16.20%

VGM Score67.84

Book Value / Share (Quarterly)$1.30

P/TBV (Annual)3.31x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)128.01%

Price vs S&P 500 (YTD)-31.52%

Gross Margin (TTM)18.30%

Net Profit Margin (TTM)-238.66%

EPS (TTM)$-1.05

10-Day Avg Trading Volume1.87M

EPS Excl Extra (TTM)$-1.05

Revenue Growth (5Y)112.99%

EPS (Annual)$-1.08

ROI (Annual)-64.13%

Gross Margin (Annual)-26.10%

Net Profit Margin (5Y Avg)-4654.61%

Cash / Share (Quarterly)$1.71

Revenue Growth QoQ (YoY)118.37%

ROA (Last FY)-48.81%

Revenue Growth TTM (YoY)292.16%

EBITD / Share (TTM)$-0.90

ROE (5Y Avg)-99.04%

Operating Margin (TTM)-210.78%

Cash Flow / Share (Annual)$-0.30

P/B Ratio6.12x

P/B Ratio (Quarterly)5.69x

Net Income / Employee (Annual)$-381,300

EV / Revenue (TTM)4.75x

Net Interest Coverage (TTM)-17.39x

ROA (TTM)-49.34%

EPS Incl Extra (Annual)$-1.08

Current Ratio (Annual)5.94x

Quick Ratio (Quarterly)4.12x

3-Month Avg Trading Volume1.85M

52-Week Price Return-4.76%

Revenue / Employee (TTM)$155,700

Tangible BV / Share (Quarterly)$1.25

P/S Ratio (Annual)6.07x

Asset Turnover (Annual)0.13x

52-Week High$2.58

Operating Margin (5Y Avg)-4610.29%

EPS Excl Extra (Annual)$-1.08

CapEx CAGR (5Y)13.07%

Tangible BV CAGR (5Y)-9.06%

26-Week Price Return8.11%

Quick Ratio (Annual)5.19x

13-Week Price Return11.11%

Total Debt / Equity (Annual)1.52x

Current Ratio (Quarterly)4.89x

Enterprise Value$557.77M

Revenue / Share Growth (5Y)53.36%

Asset Turnover (TTM)0.21x

Revenue / Employee (Annual)$100,000

Pretax Margin (Annual)-378.78%

Cash / Share (Annual)$3.53

3-Month Return Std Dev79.35%

Net Income / Employee (TTM)$-371,600

ROE (Last FY)-161.42%

Net Interest Coverage (Annual)-5.41x

EPS Basic Excl Extra (Annual)$-1.08

Receivables Turnover (TTM)3.19x

Total Debt / Equity (Quarterly)3.63x

EPS Incl Extra (TTM)$-1.05

Receivables Turnover (Annual)5.49x

ROI (TTM)-65.71%

P/S Ratio (TTM)3.90x

Pretax Margin (5Y Avg)-4933.00%

Revenue / Share (Annual)$0.28

Price vs S&P 500 (52W)-20.29%

Year-to-Date Return-19.60%

5-Day Price Return-8.05%

EPS Normalized (Annual)$-1.08

ROA (5Y Avg)-39.58%

Net Profit Margin (Annual)-381.40%

Month-to-Date Return-17.53%

Cash Flow / Share (TTM)$-0.97

EBITD / Share (Annual)$-0.99

Operating Margin (Annual)-358.87%

LT Debt / Equity (Annual)1.52x

ROI (5Y Avg)-53.19%

LT Debt / Equity (Quarterly)3.63x

EPS Basic Excl Extra (TTM)$-1.05

P/TBV (Quarterly)7.56x

P/B Ratio (Annual)2.94x

Inventory Turnover (TTM)3.34x

Pretax Margin (TTM)-238.08%

Price vs S&P 500 (13W)8.43%

Beta2.37x

Revenue / Share (TTM)$0.44

ROE (TTM)-178.66%

52-Week Low$1.18

vGradeC

gGradeA

mGradeB

vgmGradeB

AUTL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.19	-$0.15	+19.64%(+$0.04)
Q1 2026	May 14, 2026	-$0.26	-$0.27	-4.20%(-$0.01)
Q4 2025	Mar 27, 2026	-$0.27	-$0.34	-28.00%(-$0.07)
Q3 2025	Nov 12, 2025	-$0.23	-$0.30	-32.84%(-$0.07)
Q2 2025	Aug 12, 2025	-$0.24	-$0.18	+25.23%(+$0.06)

AUTL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

4.31

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AUTLAutolus Therapeutics plc American Depositary Share	C	A	B	3.9x	292.2%	18.3%	—	$1.60
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Autolus Therapeutics plc American Depositary Share

Autolus Therapeutics develops next-generation programmed T-cell therapies for cancer treatment. The biopharmaceutical company's clinical-stage pipeline is anchored by Obe-cel and includes several additional programs (AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8) at varying developmental stages.